SAN

82.47

+0.17%↑

MRK1

111.95

+1.36%↑

SHL.DE

46.92

-0.15%↓

ARGX

477.8

-0.89%↓

FRE

42.16

+0.36%↑

SAN

82.47

+0.17%↑

MRK1

111.95

+1.36%↑

SHL.DE

46.92

-0.15%↓

ARGX

477.8

-0.89%↓

FRE

42.16

+0.36%↑

SAN

82.47

+0.17%↑

MRK1

111.95

+1.36%↑

SHL.DE

46.92

-0.15%↓

ARGX

477.8

-0.89%↓

FRE

42.16

+0.36%↑

SAN

82.47

+0.17%↑

MRK1

111.95

+1.36%↑

SHL.DE

46.92

-0.15%↓

ARGX

477.8

-0.89%↓

FRE

42.16

+0.36%↑

SAN

82.47

+0.17%↑

MRK1

111.95

+1.36%↑

SHL.DE

46.92

-0.15%↓

ARGX

477.8

-0.89%↓

FRE

42.16

+0.36%↑

Search

Genfit

Closed

SectorHealthcare

3.294 -0.18

Overview

Share price change

24h

Current

Min

3.26

Max

3.39

Key metrics

By Trading Economics

Income

-59M

-29M

Sales

-53M

8M

P/E

Sector Avg

111.733

50.291

Profit margin

-358.75

Employees

180

EBITDA

-56M

-24M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+157.47% upside

Dividends

By Dow Jones

Next Earnings

22 Sept 2025

Market Stats

By TradingEconomics

Market Cap

-10M

168M

Previous open

3.47

Previous close

3.294

News Sentiment

By Acuity

37%

63%

127 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Genfit Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jun 2025, 22:09 UTC

Earnings

Alimentation Couche-Tard 4Q Profit Falls on Lower Fuel Prices, Demand

25 Jun 2025, 21:19 UTC

Acquisitions, Mergers, Takeovers

Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy

25 Jun 2025, 20:38 UTC

Earnings

Micron Technology 3Q Profit Soars as AI Boom Boosts Sales

25 Jun 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears Over Middle East Ease -- Market Talk

25 Jun 2025, 23:39 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Uncertainties -- Market Talk

25 Jun 2025, 23:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Xero Probably Sees Value in Melio's Syndication Network -- Market Talk

25 Jun 2025, 23:13 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

25 Jun 2025, 21:36 UTC

Earnings

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25 Jun 2025, 21:34 UTC

Earnings

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25 Jun 2025, 21:23 UTC

Earnings

Micron's Profit Soars as AI Boom Boosts Sales -- Update

25 Jun 2025, 21:08 UTC

Earnings

Couche-Tard 4Q Canada Same-Store Merchandise Revenues Up 3.5% >ATD.T

25 Jun 2025, 21:07 UTC

Earnings

Couche-Tard 4Q U.S. Same-Store Merchandise Revenues Down 0.4% >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Rev $16.27B >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Adj EPS 46c >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q EPS 46c >ATD.T

25 Jun 2025, 21:05 UTC

Earnings

Couche-Tard 4Q Net $439.4M >ATD.T

25 Jun 2025, 20:49 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:32 UTC

Earnings

FedEx Earnings Topped Estimates. The Stock Is Fell. -- Barrons.com

25 Jun 2025, 20:27 UTC

Earnings

Winnebago Stock Hits a 5-Year Low. What It Means for the RV Industry. -- Barrons.com

25 Jun 2025, 20:26 UTC

Earnings

These Stocks Moved the Most Today: BP, FedEx, QuantumScape, BlackBerry, Nvidia, AeroVironment, and More -- Barrons.com

25 Jun 2025, 20:24 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:10 UTC

Earnings

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25 Jun 2025, 20:04 UTC

Earnings

Micron Technology Sees 4Q Adj EPS $2.35-Adj EPS $2.65 >MU

25 Jun 2025, 20:04 UTC

Earnings

Micron Technology Sees 4Q EPS $2.14-EPS $2.44 >MU

25 Jun 2025, 20:03 UTC

Earnings

Micron Technology Sees 4Q Rev $10.4B-$11B >MU

25 Jun 2025, 20:02 UTC

Earnings

Micron Technology: On Track to Deliver Record Rev With Solid Profitability and Free Cash Flow in FY25 >MU

25 Jun 2025, 20:02 UTC

Earnings

Micron Technology: Record Rev in Fiscal 3Q With Growth Across End Markets >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q Net $1.89B >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q Adj EPS $1.91 >MU

25 Jun 2025, 20:01 UTC

Earnings

Micron Technology 3Q EPS $1.68 >MU

Peer Comparison

Price change

Genfit Forecast

Price Target

By TipRanks

157.47% upside

12 Months Forecast

Average 8.703 EUR  157.47%

High 9 EUR

Low 8.4 EUR

Based on 2 Wall Street analysts offering 12 month price targets forGenfit - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.566 / 4.12Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

127 / 380 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.